Page 5 - DIAGEN-EN

primeFISH Products Hematology

HEMATOLOGY
PANEL

17-052 ATM/ TP53 / Cent 17

The tumor suppressor TP53 gene in the 17p13.1 17 in CLL patients is associated with failure of treatment
region and the protein kinase ATM gene in the 11q22.3 with alkylating agents and shorter survival times. The
region are frequently deleted in chronic lymphocytic ATM (ataxia telangiectasia mutated) gene is located at
leukemia (CLL) conditions. Deletions of the TP53 (tumor 11q22.3, and encodes a protein kinase involved in
protein 53; alsa known as p53) gene have been detected cell cycle regulation, including TP53 activation. CLL
in patients with CLL, multiple myeloma (MM), and patients with 11q deletion show rapid disease
acute myeloid leukemia (AML). Allelic loss of the short progression and low-grade survival.
arm of chromosome

DELETION

D17S1783 RH67972
3' 5'
17p13.1
Tel Cen
D17Z1 TP53
(17p11.1-q11.1)
409 kb
NORMAL

TP53 DELETION
D11S4485 RH139918
5' 3'
Cen Tel
11q22.3
ATM
312 kb
ATM DELETION

(Not to scale)

References
Dal Bo M, et al. (2011) Genes Chromosomes Cancer 50: 633-43.
Ripollés L, et al. (2006) Cancer Genet Cytogenet 171: 57-64. www.diagen.com.tr
Stankovic et al., Blood 2004;103(1):291-300
Baliakas P, et al., Leukemia. 2014;(April):1-8
Stilgenbauer et al (2002) Leukemia 16:993-1007

PRODUCT CATALOGUE 5